MedPath

Intermittent Boluses Versus Infusion of Propofol During Gastroscopy

Not Applicable
Not yet recruiting
Conditions
Anesthesia
Interventions
Registration Number
NCT06378879
Lead Sponsor
Al-Balqa Applied University
Brief Summary

It is unclear whether continuous infusion or intermittent bolus injection of propofol is better for achieving adequate sedation during a standard upper endoscopy. The study aimed to compare the efficacy and safety of continuous infusion and intermittent bolus injection of Propofol (Diprivan) during a standard upper endoscopy. In this prospective study, patients will be randomly assigned to undergo a standard upper endoscopy with either continuous infusion (CI group) or intermittent bolus injection (BI group) of Propofol (Diprivan) administered by an anesthesiologist. The primary outcome will be to assess the quality of sedation by the endoscopist (VAS). In addition to other sedation-related parameters that will include sedation induction time (minutes), total dose of propofol (mg), recovery time (minutes) using Aldrete score, any involuntary patient movement, and adverse events.

Detailed Description

Patients of both genders, aged between 18 and 85 years old and referred to standard upper endoscopy at Luzmila Hospital will be included in the study. Patients who are pregnant, have known allergies to the drugs used or a history of sedation-related complications (i.e., severe paradoxical response, hypoxemia, bradycardia, and hypotension) or gastrectomy, are American Society of Anesthesiologist (ASA) class ≥ IV (11), or are unable to provide informed consent will be excluded from participating in the study. The patients undergoing a standard upper endoscopy will be randomly assigned to either continuous infusion (CI group) of propofol (Diprivan) with induction using benzodiazepine (2 mg Dormicum i.v.) or only intermittent bolus injection (BI group) of propofol (Diprivan) infused by an anesthesiologist. BI was defined by intermittent use of 20 mg propofol (Diprivan) boluses on demand, with a minimum period of 30 seconds between boluses to evaluate the effect of the drug. CI was defined by continuous propofol (Diprivan) infusion at a 3 mg/ kg/h rate.

The anesthesiologist will follow up the patient during the first observation period, the average time spent in the recovery area and register the requied data during the procedure using Aldrete score (a post anesthesia recovery score where a minimum score of 8 is required for discharge).

The patients' identities will be coded and the data will be kept confidential. The study protocol will be performed according to the Decalrations of Helsinki and will be applied for approval by the Institutional Review Board at Al-Balqa Applied University. Written informed consent was obtained from all patients.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Patients of both genders
  • Age between 18 and 85 years old
  • Referred to standard upper endoscopy at Luzmila Hospital
Exclusion Criteria
  • Patients who are pregnant,
  • Known allergies to the used drugs
  • History of sedation-related complications (i.e., severe paradoxical response, hypoxemia, bradycardia, and hypotension)
  • Previous history of gastrectomy,
  • Patients are American Society of Anesthesiologist (ASA) class ≥ IV ,
  • Patients are unable to provide informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Continuous infusion (CI group) of propofolPropofol 100 MG in 10 ML InjectionCI was defined by continuous propofol infusion at a 3 mg/ kg/h rate with induction using benzodiazepine (2 mg dormicum i.v.) to evaluate the effect of the drug and assess sedation induction time, total dose of propofol, recovery time, quality of sedation.
Intermittent bolus injection (BI group) of propofolPropofol 100 MG in 10 ML InjectionBI was defined by intermittent use of 20 mg propofol boluses on demand, with a minimum period of 30 seconds between boluses to evaluate the effect of the drug and assess sedation induction time, total dose of propofol, recovery time, quality of sedation.
Primary Outcome Measures
NameTimeMethod
Sedation induction time (minutes)30 minutes

Sedation induction time (minutes) is the time measured from the deep sedation induction until the patient is deeply sedated

Total dose of propofol (mg)30 minutes

Total dose of propofol (mg) used during the upper endoscopy procedure

Recovery time (minutes)30 minutes

Recovery time (minutes) is the time used for the patients to open their eyes after stoping sedation

Secondary Outcome Measures
NameTimeMethod
Involuntary movement30 minutes

Any involuntary patient movement during the endoscopy procedure under deep sedation

Adverse events30 minutes

Any adverse events occurring during the procedure such as apnea, dyspnea, hiccups, jerky movements...etc

Quality of sedation30 minutes

How deeply is the patient sedated (VAS) as assessed by the endoscopist (1 good, 2 moderate, 3 poor)

© Copyright 2025. All Rights Reserved by MedPath